Literature DB >> 10936889

p27 Expression, a cyclin dependent kinase inhibitor in breast carcinoma.

M Barbareschi1.   

Abstract

p27 KIP1 is a cyclin dependent kinase inhibitor, which may act as a potential suppressor gene. Several lines of evidence support the hypothesis that reduced p27 KIP1 expression is related to uncontrolled cell proliferation and tumorigenesis. Low immunohistochemical expression of p27 KIP1 in human neoplasm seems related to tumor progression and poor prognosis. In breast cancer, low p27 is associated with high tumour grade and loss of oestrogen receptor, and it has been suggested that low p27 KIP1 is a powerful and independent prognostic marker of poor clinical outcome. There are however some discrepant results: a few studies, some of which conducted on large series of patients, do not support an independent role of p27 KIP1 as a prognostic marker. We are indeed faced with an intriguing hypothesis, but many more studies are needed to evaluate the real value of p27 KIP1 as a prognostic marker.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10936889

Source DB:  PubMed          Journal:  Adv Clin Path        ISSN: 1125-5552


  9 in total

Review 1.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

2.  Immunohistochemical demonstration of histone H1(0) in human breast carcinoma.

Authors:  Nora N Kostova; Ljuba N Srebreva; Angel D Milev; Olga G Bogdanova; Ingemar Rundquist; Herbert H Lindner; Dimiter V Markov
Journal:  Histochem Cell Biol       Date:  2005-11-03       Impact factor: 4.304

3.  A study to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma.

Authors:  Komala Pillay; Heather McCleod; Runjan Chetty; Pauline Hall
Journal:  World J Surg Oncol       Date:  2011-03-16       Impact factor: 2.754

4.  Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.

Authors:  Aslamuzzaman Kazi; Adam Carie; Michelle A Blaskovich; Cynthia Bucher; Van Thai; Stacy Moulder; Hairuo Peng; Dora Carrico; Erin Pusateri; Warren J Pledger; Norbert Berndt; Andrew Hamilton; Saïd M Sebti
Journal:  Mol Cell Biol       Date:  2009-02-09       Impact factor: 4.272

5.  Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.

Authors:  L G Estevez; J L Fortes; E Adrover; G Peiró; M Margel; E Castellá; J M Cuevas; L Bernet; M A Segui; X Andreu
Journal:  Clin Transl Oncol       Date:  2009-01       Impact factor: 3.405

6.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

Review 7.  Measuring proliferation in breast cancer: practicalities and applications.

Authors:  Mark J Beresford; George D Wilson; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

8.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

9.  Ablation of galectin-3 induces p27(KIP1)-dependent premature senescence without oncogenic stress.

Authors:  S-J Kim; H-W Lee; H Gu Kang; S-H La; Il Ju Choi; J Y Ro; R S Bresalier; J Song; K-H Chun
Journal:  Cell Death Differ       Date:  2014-06-27       Impact factor: 15.828

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.